Cancer treatment using FTS and 2-deoxyglucose
AssigneeRamot at Tel-Aviv University Ltd.
InventorsYoel Kloog, Liat Goldberg, Michael Brownstein
Life of this patent
Estimating the term…
Abstract
Methods of treating cancer by administering effective amounts of a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2-deoxyglucose (2DG) to a patient are disclosed. Pharmaceutical compositions useful in treating cancer containing a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2DG are also disclosed.
Claims18
A pharmaceutical composition useful in the treatment of pancreatic cancer or a glioblastoma, comprising effective amounts of a Ras antagonist represented by the formula:
- wherein
- R1 represents farnesyl or geranylgeranyl;
- R2 is COOR7, or CONR7R8, wherein R7 and R8 are each independently hydrogen, alkyl or alkenyl;
- R3, R4, R5 and R6 are each independently hydrogen, alkyl, alkenyl, alkoxy, halo, trifluoromethyl, trifluoromethoxy, or alkylmercapto;
- and
- X represents S;
- or a pharmaceutically acceptable salt thereof;
- and
- 2-deoxyglucose (2DG);
- and
- a pharmaceutically acceptable carrier.
A method of treating pancreatic cancer or a glioblastoma, comprising administering to a human in need thereof effective amounts of a Ras antagonist represented by the formula:
- wherein
- R1 represents farnesyl or geranylgeranyl;
- R2 is COOR7, or CONR7R8, wherein R7 and R8 are each independently hydrogen, alkyl or alkenyl;
- R3, R4, R5 and R6 are each independently hydrogen, alkyl, alkenyl, alkoxy, halo, trifluoromethyl, trifluoromethoxy, or alkylmercapto;
- and
- X represents S;
- or a pharmaceutically acceptable salt thereof;
- and
- 2-deoxyglucose (2DG).
Dependencies are inferred from the claim text.